Researchers studying animals native to the Tibetan Plateau have identified a potential new approach to treating multiple sclerosis (MS), a neurological condition caused by the immune system attacking the protective myelin sheath around nerve fibers. This discovery centers on a gene known as Retsat, which enables yaks and antelopes to maintain brain function in the region's low-oxygen environment.

A team at Shanghai Jiao Tong University conducted experiments involving mice genetically altered to carry mutations in the Retsat gene. These mice exhibited increased levels of myelin surrounding their nerve fibers compared with normal mice. Moreover, following nerve injury, the myelin sheath in these mutant mice regenerated more rapidly and more fully than in control animals.

Further investigation revealed that mice with the Retsat mutation produced higher amounts of ATDR, a compound derived from vitamin A, within their brains. This compound appeared to facilitate the repair of the myelin sheath. In models simulating MS, administration of ATDR lessened the severity of disease symptoms, suggesting its potential therapeutic value.

Notably, ATDR is naturally present in humans, prompting researchers to consider its application as a basis for new MS treatments. While additional studies are required to confirm efficacy and safety in humans, these findings offer a promising avenue for enhancing myelin repair and managing multiple sclerosis.